For the twelve months ended Jul 31, 2026, Kestra Medical Technologies Ltd. reported $106.73M of revenue and -$149.87M of net income.
KMTS revenue was $30.97M in fiscal Q1 2027 (ended Jul 31, 2026), up 59.9% from a year earlier and up 8.1% from the prior quarter. For the full fiscal 2026 it was $95.13M, up 59.0% from fiscal 2025.
KMTS net income was -$44.09M in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$25.83M a year earlier. For the full fiscal 2026 it was -$131.61M, compared with -$113.81M in fiscal 2025.
KMTS diluted EPS was -$0.75 in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$0.50 a year earlier. For the full fiscal 2026 it was -$2.43.
KMTS free cash flow was -$40.63M in fiscal Q1 2027 (ended Jul 31, 2026), compared with -$34.44M a year earlier. For the full fiscal 2026 it was -$116.59M, compared with -$100.54M in fiscal 2025.
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 |
|---|---|---|---|
| Revenue | $95.13M | $59.81M | $27.81M |
| Cost of revenue | $46.26M | $35.60M | $27.45M |
| Gross profit | $48.86M | $24.21M | $362.0K |
| Research and development | $19.48M | $15.65M | $15.49M |
| Selling, general and admin | $164.12M | $114.94M | $69.94M |
| Operating income | -$134.74M | -$106.38M | -$85.06M |
| Interest expense | $7.55M | $7.73M | $6.23M |
| Pre-tax income | -$131.32M | -$113.68M | -$94.10M |
| Income tax | $294.0K | $135.0K | $24.0K |
| Net income | -$131.61M | -$113.81M | -$94.12M |
| EPS, basic | -$2.43 | -$5.13 | -$5.07 |
| EPS, diluted | -$2.43 | -$5.13 | -$5.07 |
| Diluted shares | 54.2M | 24.6M | 19.9M |
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 |
|---|---|---|---|
| Cash and equivalents | $99.71M | $237.93M | $8.58M |
| Short-term investments | $96.72M | - | - |
| Receivables | $14.54M | $8.08M | $2.00M |
| Current assets | $222.36M | $255.33M | $14.91M |
| Total assets | $358.46M | $295.74M | $45.95M |
| Current liabilities | $50.37M | $37.98M | $32.97M |
| Long-term debt | $42.65M | $41.10M | $42.54M |
| Total debt | $42.65M | $41.10M | $42.54M |
| Total liabilities | $98.81M | $90.34M | $78.22M |
| Shareholders' equity | $259.66M | $205.41M | -$209.38M |
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 |
|---|---|---|---|
| Operating cash flow | -$81.70M | -$77.61M | -$72.23M |
| Capital expenditures | $34.89M | $22.94M | $12.23M |
| Free cash flow | -$116.59M | -$100.54M | -$84.46M |
| Investing cash flow | -$203.28M | -$23.31M | -$12.23M |
| Financing cash flow | $147.09M | $330.26M | $77.72M |
| Stock-based compensation | $33.64M | $24.27M | $1.49M |
| Depreciation and amortization | $8.71M | $7.97M | $11.56M |
| Line item | Apr 30, 2026 | Apr 30, 2025 | Apr 30, 2024 |
|---|---|---|---|
| Revenue growth, YoY | 59.0% | 115.1% | - |
| Gross margin | 51.4% | 40.5% | 1.3% |
| Operating margin | -141.6% | -177.8% | -305.8% |
| Net margin | -138.4% | -190.3% | -338.4% |
| Free cash flow margin | -122.6% | -168.1% | -303.7% |
| Return on equity | -50.7% | -55.4% | - |
| Return on assets | -36.7% | -38.5% | -204.8% |
| Current ratio | 4.41 | 6.72 | 0.45 |
| Debt to equity | 0.16 | 0.20 | - |
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $30.97M | $28.64M | $24.55M | $22.57M | $19.37M | $17.23M | $15.09M | $14.71M | $12.78M |
| Cost of revenue | $13.47M | $12.96M | $11.65M | $11.14M | $10.52M | $9.60M | $8.54M | $8.88M | $8.58M |
| Gross profit | $17.50M | $15.68M | $12.91M | $11.42M | $8.85M | $7.63M | $6.55M | $5.83M | $4.20M |
| Research and development | $6.80M | $5.63M | $4.97M | $4.88M | $4.00M | $5.39M | $3.35M | $3.51M | $3.40M |
| Selling, general and admin | $48.36M | $49.39M | $42.70M | $38.30M | $33.73M | $50.46M | $23.80M | $21.45M | $19.23M |
| Operating income | -$37.66M | -$39.34M | -$34.77M | -$31.75M | -$28.88M | -$48.21M | -$20.60M | -$19.13M | -$18.43M |
| Interest expense | $1.93M | $1.84M | $1.89M | $1.90M | $1.91M | $1.76M | $1.78M | $2.32M | $1.87M |
| Pre-tax income | -$44.04M | -$38.64M | -$34.13M | -$32.75M | -$25.79M | -$51.01M | -$21.74M | -$20.61M | -$20.32M |
| Income tax | $50.0K | $192.0K | $35.0K | $34.0K | $33.0K | $102.0K | $18.0K | $8.0K | $7.0K |
| Net income | -$44.09M | -$38.84M | -$34.17M | -$32.78M | -$25.83M | -$52.05M | -$21.51M | -$20.62M | -$20.32M |
| EPS, basic | -$0.75 | -$0.68 | -$0.61 | -$0.64 | -$0.50 | - | -$1.25 | -$1.19 | -$1.12 |
| EPS, diluted | -$0.75 | -$0.68 | -$0.61 | -$0.64 | -$0.50 | - | -$1.25 | -$1.19 | -$1.12 |
| Diluted shares | 58.6M | - | 55.8M | 51.4M | 51.3M | - | 19.9M | 19.9M | 19.9M |
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $68.56M | $99.71M | $291.32M | $175.42M | $201.21M | $237.93M | $54.35M | $76.92M | $99.97M |
| Short-term investments | $130.35M | $96.72M | - | - | - | - | - | - | - |
| Receivables | $15.41M | $14.54M | $12.71M | $10.41M | $9.25M | $8.08M | - | - | - |
| Current assets | $226.27M | $222.36M | $314.06M | $195.41M | $220.69M | $255.33M | - | - | - |
| Total assets | $347.36M | $358.46M | $379.34M | $246.70M | $266.30M | $295.74M | - | - | - |
| Current liabilities | $48.27M | $50.37M | $42.93M | $35.76M | $32.26M | $37.98M | - | - | - |
| Long-term debt | $72.50M | $42.65M | $42.26M | $41.87M | $41.49M | $41.10M | - | - | - |
| Total debt | $72.50M | $42.65M | $42.26M | $41.87M | $41.49M | $41.10M | - | - | - |
| Total liabilities | $125.00M | $98.81M | $91.35M | $82.62M | $82.14M | $90.34M | - | - | - |
| Shareholders' equity | $222.36M | $259.66M | $287.99M | $164.08M | $184.16M | $205.41M | -$257.89M | -$236.54M | -$216.47M |
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.30M | -$18.72M | -$18.37M | -$18.34M | -$26.27M | -$24.06M | -$18.00M | -$18.06M | -$17.50M |
| Capital expenditures | $8.34M | $9.66M | $9.80M | $7.26M | $8.17M | $7.39M | $4.06M | $4.45M | $7.04M |
| Free cash flow | -$40.63M | -$28.38M | -$28.16M | -$25.61M | -$34.44M | -$31.45M | -$22.06M | -$22.50M | -$24.54M |
| Investing cash flow | -$21.35M | -$172.71M | -$14.92M | -$7.42M | -$8.23M | -$7.40M | -$4.45M | -$4.42M | -$7.03M |
| Financing cash flow | $22.50M | -$185.0K | $149.18M | -$27.0K | -$1.88M | $214.70M | -$119.0K | -$575.0K | $116.25M |
| Stock-based compensation | $9.52M | $10.30M | $10.11M | $8.65M | $4.58M | $22.31M | $459.0K | $1.12M | $377.0K |
| Depreciation and amortization | $2.66M | $2.33M | $1.98M | $2.37M | $2.03M | $1.84M | $1.89M | $1.87M | $2.38M |
| Line item | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 59.9% | 66.2% | 62.7% | 53.4% | 51.5% | - | - | - | - |
| Gross margin | 56.5% | 54.8% | 52.6% | 50.6% | 45.7% | 44.3% | 43.4% | 39.6% | 32.9% |
| Operating margin | -121.6% | -137.4% | -141.6% | -140.7% | -149.1% | -279.8% | -136.5% | -130.1% | -144.2% |
| Net margin | -142.3% | -135.6% | -139.2% | -145.3% | -133.3% | -302.1% | -142.5% | -140.2% | -159.0% |
| Free cash flow margin | -131.2% | -99.1% | -114.7% | -113.5% | -177.8% | -182.5% | -146.2% | -153.0% | -192.0% |
| Current ratio | 4.69 | 4.41 | 7.32 | 5.47 | 6.84 | 6.72 | - | - | - |
| Debt to equity | 0.33 | 0.16 | 0.15 | 0.26 | 0.23 | 0.20 | - | - | - |
Source: XBRL data Kestra Medical Technologies Ltd. files with the SEC, latest filing dated Sep 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| KMTS | $106.73M | +60.7% | -$149.87M | -140.4% | $1.70B |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $127.56B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.03B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $64.70B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.17B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $52.27B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.66B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $31.50B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $27.34B |